PDF herunterladen
Thromb Haemost 1983; 50(04): 852-856
DOI: 10.1055/s-0038-1665327
Original Article
Schattauer GmbH Stuttgart

Dipyridamole Inhibits Platelet Aggregation in Whole Blood

P Gresele
The Centre for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
,
C Zoja
The Centre for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
,
H Deckmyn
The Centre for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
,
J Arnout
The Centre for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
,
J Vermylen
The Centre for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
,
M Verstraete
The Centre for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 25. Juli 1983

Accepted 04. Oktober 1983

Publikationsdatum:
18. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Dipyridamole possesses antithrombotic properties in the animal and in man but it does not inhibit platelet aggregation in plasma. We evaluated the effect of dipyridamole ex vivo and in vitro on platelet aggregation induced by collagen and adenosine- 5’-diphosphate (ADP) in human whole blood with an impedance aggregometer. Two hundred mg dipyridamole induced a significant inhibition of both ADP- and collagen-induced aggregation in human blood samples taken 2 hr after oral drug intake. Administration of the drug for four days, 400 mg/day, further increased the antiplatelet effect. A significant negative correlation was found between collagen-induced platelet aggregation in whole blood and dipyridamole levels in plasma (p <0.001). A statistically significant inhibition of both collagen (p <0.0025) and ADP-induced (p <0.005) platelet aggregation was also obtained by incubating whole blood in vitro for 2 min at 37° C with dipyridamole (3.9 μM). No such effects were seen in platelet-rich plasma, even after enrichment with leukocytes. Low-dose adenosine enhanced in vitro inhibition in whole blood.

Our results demonstrate that dipyridamole impedes platelet aggregation in whole blood by an interaction with red blood cells, probably involving adenosine.

Keywords

Adenosine - Dipyridamole - Impedance aggregometry - Platelet aggregation - Red blood cells - Whole blood
 

  • References

  • 1 Kadatz RA. Die pharmakologischen Eigenschaften der neuen koronarerweitemden Substanz 2,6-Bis(diaethanolamino)-4,8 dipiperidino-pyrimido(5,4-d)pyrimidin. Arzneimittelforsch 1959; 9: 39-45
    PubMedGoogle Scholar
  • 2 Bunag RD, Douglas CR, Imai S, Berne RM. Influence of a pyrimidopyrimidine derivative on deamination of adenosine by blood. Circ Res 1964; 15: 83-88
    CrossrefPubMedGoogle Scholar
  • 3 Bom GV R, Cross MJ. Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J Physiol 1963; 166: 29P-30P
    CrossrefPubMedGoogle Scholar
  • 4 Emmons PR, Harrison MG J, Honour AJ, Mitchell JR. Effect of a pyrimidopyrimidine derivative on thrombus formation in the rabbit. Nature 1965; 208: 255-257
    CrossrefPubMedGoogle Scholar
  • 5 Didisheim P. Inhibition by dipyridamole of arterial thrombosis in rats. Thrombos Diathes Haemorrh 1968; 20: 256-266
    PubMedGoogle Scholar
  • 6 Mayer JE, Hammond GL. Dipyridamole and aspirin tested against an experimental model of thrombosis. Ann Surg 1973; 178: 108-112
    CrossrefPubMedGoogle Scholar
  • 7 Pumphrey CW, Fuster V, Dewanjee MK. et al Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. Am J Cardiol 1983; 51: 591-595
    CrossrefPubMedGoogle Scholar
  • 8 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
    CrossrefPubMedGoogle Scholar
  • 9 Kincaid-Smith P. Modification of the vascular lesions of rejection in cadaveric renal allografts by dipyridamole and anticoagulants. Lancet 1969; 2: 920-922
    PubMedGoogle Scholar
  • 10 Sullivan JM, Harken DW, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971; 284: 1391-1394
    CrossrefPubMedGoogle Scholar
  • 11 Packham MA, Mustard JF. Non steroidal anti-inflammatory drugs, pyrimido-pyrimidine compounds and tricyclic compounds. Effects on platelet functions In: Hirsh J, Cade JF, Gallus AS, Schonbaum E. (eds) Platelets. Drugs and Thrombosis Karger; Basel: 1975. pp 111-123
    Google Scholar
  • 12 Weiss HJ. Antiplatelet therapy. N Engl J Med 1978; 298: 1344-1347
    CrossrefPubMedGoogle Scholar
  • 13 Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; 1: 1286-1289
    PubMedGoogle Scholar
  • 14 Steer ML, MacIntyre DE, Levine L, Salzman EW. Is prostacyclin a physiologically important circulating anti-platelet agent. Nature 1980; 283: 194-195
    CrossrefPubMedGoogle Scholar
  • 15 Di Minno G, Silver MJ, de Gaetano G. Ingestion of dipyridamole reduces inhibitory effect of prostacyclin on human platelets. Lancet 1979; 2: 701-702
    PubMedGoogle Scholar
  • 16 Pickles H, Fish A, Hassan S, Burke C, Warrington S, O’Grady J. Effects of intravenous epoprostenol on platelets and the cardiovascular system are not potentiated by dipyridamole. Clin Pharmacol Ther 1983; 33: 178-182
    CrossrefPubMedGoogle Scholar
  • 17 Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999-1005
    CrossrefPubMedGoogle Scholar
  • 18 Harker LA, Hanson SR. Experimental arterial thromboembolism in baboons: mechanism, quantitation and pharmacologic prevention. J Clin Invest 1979; 64: 559-569
    CrossrefPubMedGoogle Scholar
  • 19 Buchanan MR, Hirsh J. A comparison of the effects of aspirin and dipyridamole on platelet aggregation in vivo and ex vivo. Thromb Res 1978; 13: 517-529
    CrossrefPubMedGoogle Scholar
  • 20 Packham MA, Mustard JF. Pharmacology of platelet affecting drugs. Circulation 1980; 62 (suppl V) (Suppl. 05) V26-V41
    PubMedGoogle Scholar
  • 21 Bom GV R, Görög P, Kratzer MA A. Aggregation of platelets in damaged vessels. Philos Trans R Soc London 1981; 294: 241-250
    CrossrefPubMedGoogle Scholar
  • 22 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-158
    CrossrefPubMedGoogle Scholar
  • 23 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
    CrossrefPubMedGoogle Scholar
  • 24 Challen A, Branch WJ, Cummings JH. Quantitation of platelet mass during aggregation in the electronic (Wellcome) whole blood aggregometer. J Pharmacol Methods 1982; 8: 115-122
    CrossrefPubMedGoogle Scholar
  • 25 Dresse A, Chevolet C, Delapierre D. et al Pharmacokinetics of oral dipyridamole (Persantine®) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23: 229-234
    CrossrefPubMedGoogle Scholar
  • 26 Semeraro N, Locati D, Colucci M. Leukocyte-dependent platelet activation: an alternative pathway for initiation of blood clotting in inflammation. Agents Actions 1981; 11: 553-555
    CrossrefPubMedGoogle Scholar
  • 27 Li CC. Introduction to experimental statistics. McGraw-Hill; New-York: 1964
    Google Scholar
  • 28 Philp RB, Lemieux JP V. Interactions of dipyridamole and adenosine on platelet aggregation. Nature 1969; 221: 1162-1164
    CrossrefPubMedGoogle Scholar
  • 29 Cucuianu MP, Nishizawa EE, Mustard JF. Effect of pyrimido- pyrimidine compounds on platelet function. J Lab Clin Med 1971; 77: 958-974
    PubMedGoogle Scholar
  • 30 Scherathaner G, Miihlhauser I, Silberbauer K. Beta-thromboglobulin lowered by dipyridamole in diabetes. Lancet 1979; 2: 748-749
    PubMedGoogle Scholar
  • 31 Mehta J, Mehta P, Pepine CJ, Conti CR. Platelet function studies in coronary artery disease. X. Effect of dipyridamole. Am J Cardiol 1981; 47: 1111-1114
    CrossrefPubMedGoogle Scholar
  • 32 Nenci GG, Berrettini M, Todisco T, Parise P. Enhanced plasma β-thromboglobulin in hypoxemia: effect of dipyridamole. N Engl J Med 1981; 304: 1044
    PubMedGoogle Scholar
  • 33 Subbarao K, Rucinski B, Rausch MA, Schmid K, Niewiarowski S. Binding of dipyridamole to human platelets and to at acid glycoprotein and its significance for the inhibition of adenosine uptake. J Clin Invest 1977; 60: 936-943
    CrossrefPubMedGoogle Scholar
  • 34 Nunn B, White JP N. Inhibitors of platelet aggregation have different activity in blood than in platelet-rich plasma. Br J Pharmacol 1980; 70: 163P-164P
    PubMedGoogle Scholar
  • 35 Mills DC B. The breakdown of adenosine diphosphate and of adenosine triphosphate in plasma. Biochem J 1966; 98: 32P-33P
    CrossrefPubMedGoogle Scholar
  • 36 Schrader J, Berne RM, Rubio R. Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol 1972; 223: 159-166
    PubMedGoogle Scholar
  • 37 Kolassa N, Pfleger K, Rummel W. Specificity of adenosine uptake into the heart and inhibition by dipyridamole. Eur J Pharmacol 1970; 9: 265-268
    CrossrefPubMedGoogle Scholar
  • 38 Summers A, Subbarao K, Rucinski B, Niewiarowski S. The effect of dipyridamole on adenosine uptake by platelets ex vivo. Thromb Res 1977; 11: 611-618
    CrossrefPubMedGoogle Scholar
  • 39 Crutchley DJ, Ryan US, Ryan JW. Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cul-tured cells derived from bovine pulmonary artery. J Clin Invest 1980; 66: 29-35
    CrossrefPubMedGoogle Scholar
  • 40 Roos H, Pfleger K. Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole. Mol Pharmacol 1972; 8: 417-425
    PubMedGoogle Scholar
  • 41 Sollevi A, Ostergren J, Hiemdahl P, Fredholm BB, Fagrell B. The effect of dipyridamole on plasma adenosine levels and skin microcirculation in man. J Clin Chem Clin Biochem 1982; 20: 420
    PubMedGoogle Scholar
  • 42 Haslam RJ, Lynham JA. Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine. Life Sci 1972; 11: 1143-1154
    CrossrefPubMedGoogle Scholar
  • 43 Steer ML, Salzman EW. Cyclic nucleotides in hemostasis and thrombosis. In: Hamet P, Sands H. (eds) Advances in Cyclic Nucleotide Research. Raven Press; New-York: 1980. 12 71-92
    Google Scholar
  • 44 Mills DC B, Smith JB. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3’: 5’-cyclic monophosphate in platelets. Biochem J 1971; 121: 185-196
    CrossrefPubMedGoogle Scholar
  • 45 Best LC, McGuire MB, Jones PB B. et al Mode of action of dipyridamole on human platelets. Thromb Res 1979; 16: 367-379
    CrossrefPubMed